Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Phase 2
Active, not recruiting
- Conditions
- Central Nervous System MetastasesHER2-positive Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Nancy Lin, MD
- Target Recruit Count
- 19
- Registration Number
- NCT03417544
- Locations
- ๐บ๐ธ
Northwestern University, Chicago, Illinois, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2013-03-14
- Lead Sponsor
- Nancy Lin, MD
- Target Recruit Count
- 15
- Registration Number
- NCT00496379
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
Phase 1
Completed
- Conditions
- Breast CancerBrain Metastases
- Interventions
- First Posted Date
- 2007-05-08
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- Nancy Lin, MD
- Target Recruit Count
- 35
- Registration Number
- NCT00470847
- Locations
- ๐บ๐ธ
Brigham and Women's Hospital, Boston, Massachusetts, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธIndiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
- First Posted Date
- 2007-05-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Nancy Lin, MD
- Target Recruit Count
- 87
- Registration Number
- NCT00470704
- Locations
- ๐บ๐ธ
Dana-Farber at Faulkner Hospital, Boston, Massachusetts, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath